首页 > 最新文献

International Journal of Cardiology Cardiovascular Risk and Prevention最新文献

英文 中文
Efficacy and safety of drugs in residual cardiovascular risk: A systematic review of the literature 残留心血管风险药物的疗效和安全性:文献系统回顾
IF 1.9 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-06-15 DOI: 10.1016/j.ijcrp.2024.200298
Mario Andres Hernandez-Sómerson , Fernando Montoya-Agudelo , Gustavo Huertas-Rodriguez

Background

The objective of this research is to evaluate the efficacy and safety of drugs in the residual risk in any of its three components: lipid, inflammatory and thrombotic risk.

Methods

A systematic review was conducted of randomized clinical trials that included as a primary outcome, at least one of the conditions related to atherosclerotic cardiovascular disease. The databases used were PUBMED/MEDLINE, Scopus and ClinicalTrials.gov. The risk of bias of the studies was assessed using the Risk of Bias 2 tool.

Results

and discussion: 18 studies were included in the analysis. Half of the studies had low risk of bias or some concerns. Several drugs were effective in reducing the primary outcome: ethyl eicosapentaenoeic acid (17.2 % E-EPA versus 22 % placebo HR: 0.75; 95 % CI 0.68–0.83; p < 0.001), colchicine in stable coronary artery disease (6.8 % vs placebo 9.6 %, HR 0.59, 95 % CI 0.57–0.83; p < 0.001), Canakinumab (150 mg vs placebo ARR 15 %, HR 0.85, 95 % CI 0.74–0.98; p = 0.021) and Rivaroxaban with Aspirin in stable atherosclerotic disease (4.1 % versus aspirin 5.4 %, HR 0.76, 95 % CI 0.66–0.86, P < 0.001). Serious adverse events did not differ between study groups, except for a higher rate of bleeding with the use of combination antithrombotic therapy.

Conclusion

The residual risk can be reduced through the use of different drugs that act by modifying atherogenic lipid levels, modulating inflammatory pathways and the risk of thrombosis, with an acceptable safety profile in most studies.

背景这项研究的目的是评估药物在血脂、炎症和血栓风险这三种残余风险中任何一种风险中的疗效和安全性。使用的数据库包括 PUBMED/MEDLINE、Scopus 和 ClinicalTrials.gov。结果与讨论:18 项研究被纳入分析。半数研究的偏倚风险较低或存在一些问题。有几种药物能有效降低主要结果:二十碳五烯酸乙酯(17.2% E-EPA 对 22% 安慰剂 HR:0.75;95 % CI 0.68-0.83;p <;0.001)、稳定型冠状动脉疾病中的秋水仙碱(6.8% 对安慰剂 9.6%,HR 0.59,95 % CI 0.57-0.83; P <0.001)、卡那库单抗(150 mg vs 安慰剂 ARR 15 %,HR 0.85,95 % CI 0.74-0.98; P = 0.021)和利伐沙班联合阿司匹林治疗稳定型动脉粥样硬化疾病(4.1 % vs 阿司匹林 5.4 %,HR 0.76,95 % CI 0.66-0.86, P <0.001)。研究组之间的严重不良事件没有差异,只是使用联合抗血栓疗法的出血率较高。结论通过使用不同的药物,可以降低残余风险,这些药物通过改变动脉粥样硬化脂质水平、调节炎症途径和血栓形成风险发挥作用,而且大多数研究的安全性是可以接受的。
{"title":"Efficacy and safety of drugs in residual cardiovascular risk: A systematic review of the literature","authors":"Mario Andres Hernandez-Sómerson ,&nbsp;Fernando Montoya-Agudelo ,&nbsp;Gustavo Huertas-Rodriguez","doi":"10.1016/j.ijcrp.2024.200298","DOIUrl":"10.1016/j.ijcrp.2024.200298","url":null,"abstract":"<div><h3>Background</h3><p>The objective of this research is to evaluate the efficacy and safety of drugs in the residual risk in any of its three components: lipid, inflammatory and thrombotic risk.</p></div><div><h3>Methods</h3><p>A systematic review was conducted of randomized clinical trials that included as a primary outcome, at least one of the conditions related to atherosclerotic cardiovascular disease. The databases used were PUBMED/MEDLINE, Scopus and <span>ClinicalTrials.gov</span><svg><path></path></svg>. The risk of bias of the studies was assessed using the Risk of Bias 2 tool.</p></div><div><h3>Results</h3><p>and discussion: 18 studies were included in the analysis. Half of the studies had low risk of bias or some concerns. Several drugs were effective in reducing the primary outcome: ethyl eicosapentaenoeic acid (17.2 % E-EPA versus 22 % placebo HR: 0.75; 95 % CI 0.68–0.83; p &lt; 0.001), colchicine in stable coronary artery disease (6.8 % vs placebo 9.6 %, HR 0.59, 95 % CI 0.57–0.83; p &lt; 0.001), Canakinumab (150 mg vs placebo ARR 15 %, HR 0.85, 95 % CI 0.74–0.98; p = 0.021) and Rivaroxaban with Aspirin in stable atherosclerotic disease (4.1 % versus aspirin 5.4 %, HR 0.76, 95 % CI 0.66–0.86, P &lt; 0.001). Serious adverse events did not differ between study groups, except for a higher rate of bleeding with the use of combination antithrombotic therapy.</p></div><div><h3>Conclusion</h3><p>The residual risk can be reduced through the use of different drugs that act by modifying atherogenic lipid levels, modulating inflammatory pathways and the risk of thrombosis, with an acceptable safety profile in most studies.</p></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"22 ","pages":"Article 200298"},"PeriodicalIF":1.9,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772487524000631/pdfft?md5=c9368d4e4e6a0f6d57a6fbec4dc758df&pid=1-s2.0-S2772487524000631-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141409322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lipoprotein (a) and lipid-lowering treatment from the perspective of a cardiac surgeon. An impact on the prognosis in patients with aortic valve replacement and after heart transplantation 从心脏外科医生的角度看脂蛋白(a)和降脂治疗。对主动脉瓣置换术和心脏移植术后患者预后的影响
IF 2.3 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-06-06 DOI: 10.1016/j.ijcrp.2024.200297
Stanisław Surma , Michał O. Zembala , Bogusław Okopień , Maciej Banach

Lipoprotein(a) is a recognized risk factor for ASCVD. There is still no targeted therapy for Lp(a), however, drugs such as pelacarsen, olpasiran, zerlasiran, lepodisiran and muvalaplin are in clinical trials and have been shown to be effective in significantly reducing Lp(a) levels. Moreover, elevated Lp(a) levels significantly affect the prognosis of patients after aortic valve replacement (AVR) and heart transplantation (HTx). Therefore, the assessment of Lp(a) concentration in these patients will allow for a more accurate stratification of their cardiovascular risk, and the possibility of lowering Lp(a) will allow for the optimization of this risk. In this article, we summarized the most important information regarding the role of Lp(a) and lipid-lowering treatment in patients after AVR and HTx.

脂蛋白(a)是公认的急性心血管疾病的危险因素。目前还没有针对脂蛋白(a)的靶向治疗方法,不过,佩拉卡森、奥帕西兰、泽拉西兰、利波地西兰和缪瓦拉普林等药物已进入临床试验阶段,并被证明能有效显著降低脂蛋白(a)水平。此外,Lp(a)水平升高会严重影响主动脉瓣置换术(AVR)和心脏移植术(HTx)患者的预后。因此,评估这些患者的脂蛋白(a)浓度将有助于更准确地对其心血管风险进行分层,而降低脂蛋白(a)的可能性将有助于优化这种风险。在这篇文章中,我们总结了有关 Lp(a) 和降脂治疗在 AVR 和 HTx 患者中的作用的最重要信息。
{"title":"Lipoprotein (a) and lipid-lowering treatment from the perspective of a cardiac surgeon. An impact on the prognosis in patients with aortic valve replacement and after heart transplantation","authors":"Stanisław Surma ,&nbsp;Michał O. Zembala ,&nbsp;Bogusław Okopień ,&nbsp;Maciej Banach","doi":"10.1016/j.ijcrp.2024.200297","DOIUrl":"https://doi.org/10.1016/j.ijcrp.2024.200297","url":null,"abstract":"<div><p>Lipoprotein(a) is a recognized risk factor for ASCVD. There is still no targeted therapy for Lp(a), however, drugs such as pelacarsen, olpasiran, zerlasiran, lepodisiran and muvalaplin are in clinical trials and have been shown to be effective in significantly reducing Lp(a) levels. Moreover, elevated Lp(a) levels significantly affect the prognosis of patients after aortic valve replacement (AVR) and heart transplantation (HTx). Therefore, the assessment of Lp(a) concentration in these patients will allow for a more accurate stratification of their cardiovascular risk, and the possibility of lowering Lp(a) will allow for the optimization of this risk. In this article, we summarized the most important information regarding the role of Lp(a) and lipid-lowering treatment in patients after AVR and HTx.</p></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"22 ","pages":"Article 200297"},"PeriodicalIF":2.3,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277248752400062X/pdfft?md5=ece16801c983d7af3acc1740f98b7385&pid=1-s2.0-S277248752400062X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141290803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Referral of the heart failure patient from cardiology and internal medicine department: Same patients and same rehabilitative approach? 心内科和内科转诊的心力衰竭患者:同样的病人和同样的康复方法?
IF 2.3 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-06-01 DOI: 10.1016/j.ijcrp.2024.200277
Venturini Elio
{"title":"Referral of the heart failure patient from cardiology and internal medicine department: Same patients and same rehabilitative approach?","authors":"Venturini Elio","doi":"10.1016/j.ijcrp.2024.200277","DOIUrl":"https://doi.org/10.1016/j.ijcrp.2024.200277","url":null,"abstract":"","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"21 ","pages":"Article 200277"},"PeriodicalIF":2.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772487524000424/pdfft?md5=d664969e5f258bb09759e9db694b9fc5&pid=1-s2.0-S2772487524000424-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141249812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What the ITACARE-P Light-Heart and Sweet-Heart projects have taught us ITACARE-P Light-Heart 和 Sweet-Heart 项目带给我们的启示
IF 2.3 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-06-01 DOI: 10.1016/j.ijcrp.2024.200274
Bruno Passaretti

Sweet Heart and Light Heart represent the first two educational formats of ITACARE-P, a recently established scientific association that joins various professionals with the aim of promoting all activities related to Cardiac Prevention and Rehabilitation. These educational formats represent opportunities for updating, comparing and sharing ideas among experts in order to standardize behaviors on hot topics. Pathologies in the metabolic field were chosen: diabetes mellitus and obesity, especially due to the cardiologist's possibility of prescribing drugs belonging to the SGLT2-i and GLP-RA classes, which have been shown to have a cardioprotective and nephroprotective effect, thus carrying a favorable influence on cardiovascular mortality. Sweet Heart and Light Heart were structured in a series of lectures alternated with “peer-to-peer” discussions; the possibilities offered by Italian National Health Service refundability in the prescription of these drugs and the difficulties that can be encountered in communicating this therapy to patients, particularly in the case of obesity where the purchase of the drug is at the patient's own expense, were examined. The results of this initiative was the drafting and publication of a position paper involving the entire Scientific Committee of the Association concerning the management of the patient suffering from diabetes mellitus in Cardiac Rehabilitation, with the peculiarities that concern the approach to the patient in this setting, such as the prescription of physical exercise in the same way as a drug, the introduction of process and outcome indicators, and the search for an anti-atherogenic or rather hemodynamic effect.

ITACARE-P 是一个新近成立的科学协会,它联合了各种专业人士,旨在促进与心脏预防和康复有关的所有活动。这些教育形式为专家们提供了更新、比较和交流思想的机会,以便就热门话题规范行为。我们选择了代谢领域的病症:糖尿病和肥胖症,特别是因为心脏病医生可以使用 SGLT2-i 和 GLP-RA 类药物,这些药物已被证明具有保护心脏和肾脏的作用,从而对心血管疾病的死亡率产生有利影响。甜蜜之心 "和 "光明之心 "通过一系列讲座与 "同行 "讨论交替进行;研究了意大利国家医疗服务机构在处方这些药物时提供退款的可能性,以及在向患者宣传这种疗法时可能遇到的困难,特别是在肥胖症患者自费购药的情况下。这一举措的成果是起草并出版了一份由协会科学委员会全体成员参与的立场文件,内容涉及在心脏康复过程中对糖尿病患者的管理,以及在这种情况下对患者采取的特殊方法,例如以与药物相同的方式开具体育锻炼处方,引入过程和结果指标,以及寻求抗动脉粥样硬化或血液动力学效应。
{"title":"What the ITACARE-P Light-Heart and Sweet-Heart projects have taught us","authors":"Bruno Passaretti","doi":"10.1016/j.ijcrp.2024.200274","DOIUrl":"https://doi.org/10.1016/j.ijcrp.2024.200274","url":null,"abstract":"<div><p>Sweet Heart and Light Heart represent the first two educational formats of ITACARE-P, a recently established scientific association that joins various professionals with the aim of promoting all activities related to Cardiac Prevention and Rehabilitation. These educational formats represent opportunities for updating, comparing and sharing ideas among experts in order to standardize behaviors on hot topics. Pathologies in the metabolic field were chosen: diabetes mellitus and obesity, especially due to the cardiologist's possibility of prescribing drugs belonging to the SGLT2-i and GLP-RA classes, which have been shown to have a cardioprotective and nephroprotective effect, thus carrying a favorable influence on cardiovascular mortality. Sweet Heart and Light Heart were structured in a series of lectures alternated with “peer-to-peer” discussions; the possibilities offered by Italian National Health Service refundability in the prescription of these drugs and the difficulties that can be encountered in communicating this therapy to patients, particularly in the case of obesity where the purchase of the drug is at the patient's own expense, were examined. The results of this initiative was the drafting and publication of a position paper involving the entire Scientific Committee of the Association concerning the management of the patient suffering from diabetes mellitus in Cardiac Rehabilitation, with the peculiarities that concern the approach to the patient in this setting, such as the prescription of physical exercise in the same way as a drug, the introduction of process and outcome indicators, and the search for an anti-atherogenic or rather hemodynamic effect.</p></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"21 ","pages":"Article 200274"},"PeriodicalIF":2.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772487524000394/pdfft?md5=fba3dc824fa9bdca53c39b96b93f35b9&pid=1-s2.0-S2772487524000394-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141249811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advanced machine learning for estimating vascular occlusion percentage in patients with ischemic heart disease and periodontitis 利用先进的机器学习估算缺血性心脏病和牙周炎患者的血管闭塞百分比
IF 2.3 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-06-01 DOI: 10.1016/j.ijcrp.2024.200291
Pradeep Kumar Yadalam, Santhosh B. Shenoy, Raghavendra Vamsi Anegundi, Seyed Ali Mosaddad, Artak Heboyan

Objective

The study aimed to assess the efficacy of advanced machine learning algorithms in estimating the percentage of vascular occlusion in ischemic heart disease (IHD) cases with periodontitis.

Methods

This study involved 300 IHD patients aged 45 to 65 with stage III periodontitis undergoing coronary angiograms. Dental and periodontal examinations assessed various factors. Coronary angiograms categorized patients into three groups based on artery stenosis. Clinical data were processed, outliers were identified, and machine learning algorithms were applied for analysis using the orange tool, including confusion matrices and receiver operating characteristic (ROC) curves for assessment.

Results

The results showed that Random Forest, Naïve Bayes, and Neural Networks were 97 %, 84 %, and 92 % accurate, respectively. Random Forest did exceptionally well in identifying the severity of conditions, with 95.70 % accuracy for mild cases, 84.80 % for moderate cases, and a perfect 100.00 % for severe cases.

Conclusions

The current study, using Periodontal Inflammatory Surface Area (PISA) scores, revealed that the Random Forest model accurately predicted the percentage of vascular occlusion.

目的本研究旨在评估先进的机器学习算法在估计患有牙周炎的缺血性心脏病(IHD)病例中血管闭塞比例方面的功效。方法本研究涉及 300 名 45 至 65 岁、患有 III 期牙周炎的 IHD 患者,他们都接受了冠状动脉造影检查。牙科和牙周检查评估了各种因素。冠状动脉造影根据动脉狭窄程度将患者分为三组。结果结果显示,随机森林、奈夫贝叶斯和神经网络的准确率分别为 97%、84% 和 92%。随机森林在识别病情严重程度方面表现出色,轻度病例的准确率为 95.70%,中度病例的准确率为 84.80%,重度病例的准确率为 100.00%。
{"title":"Advanced machine learning for estimating vascular occlusion percentage in patients with ischemic heart disease and periodontitis","authors":"Pradeep Kumar Yadalam,&nbsp;Santhosh B. Shenoy,&nbsp;Raghavendra Vamsi Anegundi,&nbsp;Seyed Ali Mosaddad,&nbsp;Artak Heboyan","doi":"10.1016/j.ijcrp.2024.200291","DOIUrl":"10.1016/j.ijcrp.2024.200291","url":null,"abstract":"<div><h3>Objective</h3><p>The study aimed to assess the efficacy of advanced machine learning algorithms in estimating the percentage of vascular occlusion in ischemic heart disease (IHD) cases with periodontitis.</p></div><div><h3>Methods</h3><p>This study involved 300 IHD patients aged 45 to 65 with stage III periodontitis undergoing coronary angiograms. Dental and periodontal examinations assessed various factors. Coronary angiograms categorized patients into three groups based on artery stenosis. Clinical data were processed, outliers were identified, and machine learning algorithms were applied for analysis using the orange tool, including confusion matrices and receiver operating characteristic (ROC) curves for assessment.</p></div><div><h3>Results</h3><p>The results showed that Random Forest, Naïve Bayes, and Neural Networks were 97 %, 84 %, and 92 % accurate, respectively. Random Forest did exceptionally well in identifying the severity of conditions, with 95.70 % accuracy for mild cases, 84.80 % for moderate cases, and a perfect 100.00 % for severe cases.</p></div><div><h3>Conclusions</h3><p>The current study, using Periodontal Inflammatory Surface Area (PISA) scores, revealed that the Random Forest model accurately predicted the percentage of vascular occlusion.</p></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"21 ","pages":"Article 200291"},"PeriodicalIF":2.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772487524000564/pdfft?md5=c8cfbdc7eccef6e783d03ba3ec286019&pid=1-s2.0-S2772487524000564-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141138296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex and gender differences in patients with acute coronary syndromes 急性冠状动脉综合征患者的性别差异
IF 2.3 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-06-01 DOI: 10.1016/j.ijcrp.2024.200276
Alessandra Pratesi
{"title":"Sex and gender differences in patients with acute coronary syndromes","authors":"Alessandra Pratesi","doi":"10.1016/j.ijcrp.2024.200276","DOIUrl":"10.1016/j.ijcrp.2024.200276","url":null,"abstract":"","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"21 ","pages":"Article 200276"},"PeriodicalIF":2.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772487524000412/pdfft?md5=b731f7b4008453124b5c5571502c5e0d&pid=1-s2.0-S2772487524000412-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141041858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of the biomarker score in determining the risk of heart failure in diabetics in Goma, North Kivu in the Democractic Republic of the Congo 利用生物标志物评分确定刚果民主共和国北基伍戈马糖尿病患者的心力衰竭风险
IF 2.3 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-06-01 DOI: 10.1016/j.ijcrp.2024.200263
Ferdinand Ng'ekieb Mukoso, Aliocha Natuhoyila Nkodila, Hippolyte Nani tuma Situakibanza, Stannislas Okitotsho Wembonyama, Zacharie Kibendelwa Tsongo

Background

The use of biomarkers, such as N-terminal pro-brain natriuretic peptide (NTpBNP), high-sensitivity C-reactive protein (hs-CRP) and high-sensitivity troponin (hs-TnI) is an alternative approach to detect the risk of heart failure (HF), but data on this approach are fragmentary in sub-Saharan Africa. The objective of this study is to determine the correlation between the risk of heart failure and the score of biomarkers in the population of asymptomatic diabetics in the city of GOMA.

Methods

Asymptomatic diabetics in the city of Goma were cross-sectionally recruited at the Center of the Association of Diabetics in Congo (ADIC) in Goma, DRC during the period from February 5 to 19, 2023. The risk of insufficiency heart rate at 5 years was determined using pulse pressure. The biomarker score was calculated using NTproBNP, hs-CRP, hs-troponin and left ventricular hypertrophy (LVH). The association between the risk of heart failure and the biomarker score was evaluated using the logistic regression test at the threshold of p < 0.05.

Results

Of a total of 408 diabetic patients examined, 29.9% had presented a risk of heart failure. The risk of heart failure was higher in patients with a high biomarker score (57.7%), in patients with type 1 diabetes (60%) and in patients with type 2 diabetes (57.1%). Independent risk of biomarker score on occurrence of heart failure. The risk of heart failure was multiplied by 2 if the biomarker score was intermediate (OR: 2.19, 95% CI: 1.11–4.34) and by 5 if the biomarker score was high (OR: 4.73, 95% CI: 1.84–6.20).

Conclusion

The biomarker score is associated with the risk of heart failure in our study via the increase in the score elements as reported in European studies.

背景使用N末端前脑钠尿肽(NTpBNP)、高敏C反应蛋白(hs-CRP)和高敏肌钙蛋白(hs-TnI)等生物标志物是检测心力衰竭(HF)风险的另一种方法,但在撒哈拉以南非洲有关这种方法的数据很零散。本研究的目的是确定戈马市无症状糖尿病患者的心衰风险与生物标志物评分之间的相关性。方法:2023 年 2 月 5 日至 19 日期间,在刚果(金)戈马的刚果糖尿病患者协会(ADIC)中心横向招募戈马市无症状糖尿病患者。使用脉压测定5年后心率不足的风险。利用 NTproBNP、hs-CRP、hs-troponin 和左心室肥厚(LVH)计算生物标志物得分。结果 在接受检查的 408 名糖尿病患者中,29.9% 有心力衰竭风险。生物标志物得分高的患者(57.7%)、1 型糖尿病患者(60%)和 2 型糖尿病患者(57.1%)发生心力衰竭的风险更高。生物标志物评分对心衰发生的独立风险。结论在我们的研究中,生物标志物评分与心力衰竭的风险相关,这与欧洲研究报告的评分元素增加有关。
{"title":"Use of the biomarker score in determining the risk of heart failure in diabetics in Goma, North Kivu in the Democractic Republic of the Congo","authors":"Ferdinand Ng'ekieb Mukoso,&nbsp;Aliocha Natuhoyila Nkodila,&nbsp;Hippolyte Nani tuma Situakibanza,&nbsp;Stannislas Okitotsho Wembonyama,&nbsp;Zacharie Kibendelwa Tsongo","doi":"10.1016/j.ijcrp.2024.200263","DOIUrl":"10.1016/j.ijcrp.2024.200263","url":null,"abstract":"<div><h3>Background</h3><p>The use of biomarkers, such as N-terminal pro-brain natriuretic peptide (NTpBNP), high-sensitivity C-reactive protein (hs-CRP) and high-sensitivity troponin (hs-TnI) is an alternative approach to detect the risk of heart failure (HF), but data on this approach are fragmentary in sub-Saharan Africa. The objective of this study is to determine the correlation between the risk of heart failure and the score of biomarkers in the population of asymptomatic diabetics in the city of GOMA.</p></div><div><h3>Methods</h3><p>Asymptomatic diabetics in the city of Goma were cross-sectionally recruited at the Center of the Association of Diabetics in Congo (ADIC) in Goma, DRC during the period from February 5 to 19, 2023. The risk of insufficiency heart rate at 5 years was determined using pulse pressure. The biomarker score was calculated using NTproBNP, hs-CRP, hs-troponin and left ventricular hypertrophy (LVH). The association between the risk of heart failure and the biomarker score was evaluated using the logistic regression test at the threshold of p &lt; 0.05.</p></div><div><h3>Results</h3><p>Of a total of 408 diabetic patients examined, 29.9% had presented a risk of heart failure. The risk of heart failure was higher in patients with a high biomarker score (57.7%), in patients with type 1 diabetes (60%) and in patients with type 2 diabetes (57.1%). Independent risk of biomarker score on occurrence of heart failure. The risk of heart failure was multiplied by 2 if the biomarker score was intermediate (OR: 2.19, 95% CI: 1.11–4.34) and by 5 if the biomarker score was high (OR: 4.73, 95% CI: 1.84–6.20).</p></div><div><h3>Conclusion</h3><p>The biomarker score is associated with the risk of heart failure in our study via the increase in the score elements as reported in European studies.</p></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"21 ","pages":"Article 200263"},"PeriodicalIF":2.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277248752400028X/pdfft?md5=5c0ab8482917b84a04eebd6a9889188b&pid=1-s2.0-S277248752400028X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140399853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gender difference in long-term effect of cardiac rehabilitation; data from CRAGE-extra study 心脏康复长期效果的性别差异;来自 CRAGE-extra 研究的数据
IF 2.3 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-06-01 DOI: 10.1016/j.ijcrp.2024.200273
Giulia Nicolaio , Samuele Baldasseroni , Maria Vittoria Silverii , Francesca Marchetti , Costanza Burgisser , Davide Montini , Francesco Orso , Alessandra Pratesi , Andrea Ungar , Niccolò Marchionni , Francesco Fattirolli

Introduction

The positive effect of cardiac rehabilitation (CR) is demonstrated in younger and older patients. However, it is quite debated whether the beneficial effect is similarly maintained in both genders during follow-up.

Aim

to determine if the improvement obtained after CR remained significant at 1-year follow-up in older population, testing the influence of gender on this outcome.

Methods

All patients aged 75+ years consecutively referred to Cardiac Rehabilitation outpatient Unit at Careggi University Hospital were screened for eligibility. All patients attended a CR program, based on 5-day-per-week aerobic training sessions for 4 weeks and they were evaluated at the end of CR at 6 and 12 months of follow-up.

Results

361 patients with a mean age 80.6 ± 4.4 years with a complete 1-year follow-up were enrolled in the study, 87.5 % of them had an acute coronary event, and 27.6 % were females. The increase in exercise capacity at the end of CR and at 1-year follow-up was statistically significant (VO2 peak: +8.7 % in males p < 0.001, +8.5 % in females p < 0.001; distance walked at 6-min test: +7.3 % in males p < 0.001, +10.2 % in females p < 0.001, respectively); the trajectory of exercise improvement at 6 and 12 months of FU was similar in men and women without significant decrease (VO2 peak-ml/kg/min: CR discharge vs 1 year FU = 15.2 vs 15,0 p: NS; distance walked-meters: CR discharge vs 1 year FU = 445.5 vs 440.6, p: NS) from end of CR to 1-year.

Conclusions

the improvement in exercise tolerance obtained with CR program is still maintained at 1-year FU without significant influence of gender in our very old population.

导言:心脏康复(CR)对年轻和老年患者都有积极作用。方法筛选所有连续转诊至凯瑞吉大学医院心脏康复门诊部的 75 岁以上患者。结果361名平均年龄为(80.6±4.4)岁、随访时间为1年的患者参加了研究,其中87.5%的患者曾发生过急性冠状动脉事件,27.6%为女性。在 CR 结束时和随访 1 年后,运动能力的提高具有显著的统计学意义(VO2 峰值:男性 +8.7 %,女性 +8.7 %,男性 +8.7 %,女性 +8.7 %):男性为 +8.7 % p < 0.001,女性为 +8.5 % p < 0.001;6 分钟测试步行距离:分别为男性 +7.3 % p < 0.001,女性 +10.2 % p < 0.001);男性和女性在 FU 6 个月和 12 个月时的运动改善轨迹相似,没有显著下降(VO2 峰值-ml/kg/min:CR 出院 vs FU 1 年 = 15.2 vs 15,0 p. NS;步行距离-米:CR 出院 vs FU 1 年 = 15.2 vs 15,0 p. NS;步行距离-米:CR 出院 vs FU 1 年 = 15.2 vs 15,0 p. NS):NS;步行距离-米:CR出院 vs 1年FU = 445.5 vs 440.6, p. NS):结论:在我们的高龄人群中,通过 CR 计划获得的运动耐量改善在 1 年的 FU 中仍能保持,性别没有显著影响。
{"title":"Gender difference in long-term effect of cardiac rehabilitation; data from CRAGE-extra study","authors":"Giulia Nicolaio ,&nbsp;Samuele Baldasseroni ,&nbsp;Maria Vittoria Silverii ,&nbsp;Francesca Marchetti ,&nbsp;Costanza Burgisser ,&nbsp;Davide Montini ,&nbsp;Francesco Orso ,&nbsp;Alessandra Pratesi ,&nbsp;Andrea Ungar ,&nbsp;Niccolò Marchionni ,&nbsp;Francesco Fattirolli","doi":"10.1016/j.ijcrp.2024.200273","DOIUrl":"https://doi.org/10.1016/j.ijcrp.2024.200273","url":null,"abstract":"<div><h3>Introduction</h3><p>The positive effect of cardiac rehabilitation (CR) is demonstrated in younger and older patients. However, it is quite debated whether the beneficial effect is similarly maintained in both genders during follow-up.</p></div><div><h3>Aim</h3><p>to determine if the improvement obtained after CR remained significant at 1-year follow-up in older population, testing the influence of gender on this outcome.</p></div><div><h3>Methods</h3><p>All patients aged 75+ years consecutively referred to Cardiac Rehabilitation outpatient Unit at Careggi University Hospital were screened for eligibility. All patients attended a CR program, based on 5-day-per-week aerobic training sessions for 4 weeks and they were evaluated at the end of CR at 6 and 12 months of follow-up.</p></div><div><h3>Results</h3><p>361 patients with a mean age 80.6 ± 4.4 years with a complete 1-year follow-up were enrolled in the study, 87.5 % of them had an acute coronary event, and 27.6 % were females. The increase in exercise capacity at the end of CR and at 1-year follow-up was statistically significant (VO2 peak: +8.7 % in males p &lt; 0.001, +8.5 % in females p &lt; 0.001; distance walked at 6-min test: +7.3 % in males p &lt; 0.001, +10.2 % in females p &lt; 0.001, respectively); the trajectory of exercise improvement at 6 and 12 months of FU was similar in men and women without significant decrease (VO2 peak-ml/kg/min: CR discharge vs 1 year FU = 15.2 vs 15,0 p: NS; distance walked-meters: CR discharge vs 1 year FU = 445.5 vs 440.6, p: NS) from end of CR to 1-year.</p></div><div><h3>Conclusions</h3><p>the improvement in exercise tolerance obtained with CR program is still maintained at 1-year FU without significant influence of gender in our very old population.</p></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"21 ","pages":"Article 200273"},"PeriodicalIF":2.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772487524000382/pdfft?md5=987bf53d191bc025b8a7fe073f1ce788&pid=1-s2.0-S2772487524000382-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141249848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of atherosclerotic cardiovascular disease (ASCVD) and Framingham risk scores (FRS) in an Iranian population 伊朗人群动脉粥样硬化性心血管疾病 (ASCVD) 与弗雷明汉风险评分 (FRS) 的比较
IF 2.3 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-06-01 DOI: 10.1016/j.ijcrp.2024.200287
Matin Sepehrinia , Hossein Pourmontaseri , Mehrab Sayadi , Mohammad Mehdi Naghizadeh , Reza Homayounfar , Mojtaba Farjam , Azizallah Dehghan , Abdulhakim Alkamel

Background

Framingham risk score (FRS) and Atherosclerotic Cardiovascular Disease risk score (ASCVDrs) are widely used tools developed based on the American population. This study aimed to compare the ASCVDrs and FRS in an Iranian population.

Method

The participants of the Fasa Adult Cohort Study and the patients of the cardiovascular database of Vali-Asr Hospital of Fasa, aged 40–80 years, were involved in the present cross-sectional study. After excluding non-eligible participants, the individuals with a history of myocardial infarction or admission to the cardiology ward due to heart failure were considered high-risk, and the others were considered low-risk. The discriminative ability of FRS and ASCVDrs was evaluated and compared using receiver operating characteristic curve analysis. The correlation and agreement of ASCVDrs and FRS were tested using Cohen Kappa and Spearman.

Results

Finally, 8983 individuals (mean age:53.9 ± 9.5 y, 49.2 % male), including 1827 high-risk participants, entered the study. ASCVDrs detected a greater portion of participants as high-risk in comparison with FRS (28.7 % vs. 15.7 %). ASVD (AUC:0.794) had a higher discriminative ability than FRS (AUC:0.746), and both showed better discrimination in women. Optimal cut-off points for both ASCVDrs (4.36 %) and FRS (9.05 %) were lower than the original ones and in men. Compared to FRS, ASCVDrs had a higher sensitivity (79.3 % vs. 71.6 %) and lower specificity (64.5 % vs. 65.1 %). FRS and ASCVDrs had a moderate agreement (kappa:0.593,p-value<0.001) and were significantly correlated (Spearman:0.772,p-value<0.001).

Conclusions

ASCVDrs had a more accurate prediction of cardiovascular events and identified a larger number of people as high-risk in the Iranian population.

背景弗雷明汉风险评分(FRS)和动脉粥样硬化性心血管疾病风险评分(ASCVDrs)是根据美国人群开发的广泛使用的工具。本研究旨在比较 ASCVDrs 和 FRS 在伊朗人群中的应用情况。方法:本横断面研究的对象是法萨成人队列研究(Fasa Adult Cohort Study)的参与者和法萨瓦利-阿斯尔医院(Vali-Asr Hospital of Fasa)心血管数据库的患者,年龄在 40-80 岁之间。在排除不符合条件的参与者后,有心肌梗死病史或因心力衰竭入住心脏病病房的人被视为高危人群,其他人被视为低危人群。采用接收器操作特征曲线分析法对 FRS 和 ASCVDrs 的判别能力进行了评估和比较。结果最终有 8983 人(平均年龄:53.9 ± 9.5 岁,49.2% 为男性)参与了研究,其中包括 1827 名高风险参与者。与 FRS 相比,ASCVDs 检测出的高危人群比例更高(28.7% 对 15.7%)。ASVD(AUC:0.794)比 FRS(AUC:0.746)具有更高的判别能力,两者对女性的判别能力都更强。ASCVDrs(4.36%)和FRS(9.05%)的最佳临界点均低于原始临界点,且男性的临界点也低于原始临界点。与 FRS 相比,ASCVDrs 的灵敏度更高(79.3% 对 71.6%),特异性更低(64.5% 对 65.1%)。结论ASCVDrs能更准确地预测心血管事件,并能在伊朗人群中识别出更多的高危人群。
{"title":"Comparison of atherosclerotic cardiovascular disease (ASCVD) and Framingham risk scores (FRS) in an Iranian population","authors":"Matin Sepehrinia ,&nbsp;Hossein Pourmontaseri ,&nbsp;Mehrab Sayadi ,&nbsp;Mohammad Mehdi Naghizadeh ,&nbsp;Reza Homayounfar ,&nbsp;Mojtaba Farjam ,&nbsp;Azizallah Dehghan ,&nbsp;Abdulhakim Alkamel","doi":"10.1016/j.ijcrp.2024.200287","DOIUrl":"10.1016/j.ijcrp.2024.200287","url":null,"abstract":"<div><h3>Background</h3><p>Framingham risk score (FRS) and Atherosclerotic Cardiovascular Disease risk score (ASCVDrs) are widely used tools developed based on the American population. This study aimed to compare the ASCVDrs and FRS in an Iranian population.</p></div><div><h3>Method</h3><p>The participants of the Fasa Adult Cohort Study and the patients of the cardiovascular database of Vali-Asr Hospital of Fasa, aged 40–80 years, were involved in the present cross-sectional study. After excluding non-eligible participants, the individuals with a history of myocardial infarction or admission to the cardiology ward due to heart failure were considered high-risk, and the others were considered low-risk. The discriminative ability of FRS and ASCVDrs was evaluated and compared using receiver operating characteristic curve analysis. The correlation and agreement of ASCVDrs and FRS were tested using Cohen Kappa and Spearman.</p></div><div><h3>Results</h3><p>Finally, 8983 individuals (mean age:53.9 ± 9.5 y, 49.2 % male), including 1827 high-risk participants, entered the study. ASCVDrs detected a greater portion of participants as high-risk in comparison with FRS (28.7 % vs. 15.7 %). ASVD (AUC:0.794) had a higher discriminative ability than FRS (AUC:0.746), and both showed better discrimination in women. Optimal cut-off points for both ASCVDrs (4.36 %) and FRS (9.05 %) were lower than the original ones and in men. Compared to FRS, ASCVDrs had a higher sensitivity (79.3 % vs. 71.6 %) and lower specificity (64.5 % vs. 65.1 %). FRS and ASCVDrs had a moderate agreement (kappa:0.593,<em>p</em>-value&lt;0.001) and were significantly correlated (Spearman:0.772,<em>p</em>-value&lt;0.001).</p></div><div><h3>Conclusions</h3><p>ASCVDrs had a more accurate prediction of cardiovascular events and identified a larger number of people as high-risk in the Iranian population.</p></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"21 ","pages":"Article 200287"},"PeriodicalIF":2.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772487524000527/pdfft?md5=9b720b85c13a848f10fdf7f8fbb6b239&pid=1-s2.0-S2772487524000527-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141143378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of obesity with liraglutide in cardiovascular prevention: Case series by the “ITACARE-P Light-Heart Lab” working group 利拉鲁肽治疗肥胖症,预防心血管疾病:ITACARE-P轻型心脏实验室 "工作组的病例系列
IF 2.3 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-06-01 DOI: 10.1016/j.ijcrp.2024.200272
Francesco Maranta , Francesca Buffoli , Vittorio Giudici , Gabriella Malfatto , Alessandro Maloberti , Luigi Maresca , Bruno Passaretti , Anna Torri , Roberto Turato , Marco Ambrosetti
{"title":"Treatment of obesity with liraglutide in cardiovascular prevention: Case series by the “ITACARE-P Light-Heart Lab” working group","authors":"Francesco Maranta ,&nbsp;Francesca Buffoli ,&nbsp;Vittorio Giudici ,&nbsp;Gabriella Malfatto ,&nbsp;Alessandro Maloberti ,&nbsp;Luigi Maresca ,&nbsp;Bruno Passaretti ,&nbsp;Anna Torri ,&nbsp;Roberto Turato ,&nbsp;Marco Ambrosetti","doi":"10.1016/j.ijcrp.2024.200272","DOIUrl":"https://doi.org/10.1016/j.ijcrp.2024.200272","url":null,"abstract":"","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"21 ","pages":"Article 200272"},"PeriodicalIF":2.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772487524000370/pdfft?md5=8cdaeda168f6dedddc27e2ef49cb3172&pid=1-s2.0-S2772487524000370-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141249847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Cardiology Cardiovascular Risk and Prevention
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1